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O ff-pump coronary artery bypass grafting(OPCABG) requires a period of coronary artery
occlusion to accomplish a bloodless field. This obligate
coronary occlusion may be superimposed on pre-exist-
ing ischemia of varying degrees, especially in acute
evolving infarction in which blood flow is totally
occluded. In addition, off-pump surgical techniques
have limited the strategies to protect the heart from
ischemia or reperfusion injury. Reperfusion has been
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postulated to produce lethal injury to cells that are still
alive at the time of reperfusion, and therefore reperfu-
sion injury limits its potential benefit on myocardial
salvage.1,2 To avoid prolonged ischemia and possible
reperfusion injury, we recently introduced perfusion-
assisted direct coronary artery bypass (PADCAB),3 a
novel technique by which to perfuse the grafted vessels
by using a computer-controlled blood delivery system
during multivessel OPCABG. This technique allows
rapid perfusion of grafted segments before completion
of the proximal anastomosis.
Although many studies have identified effective car-
dioprotective agents to attenuate ischemia-reperfusion
(I-R) injury,1,2 a clinically useful strategy to protect the
ischemic myocardium has not been developed for
OPCABG when extracorporeal circulation and cardio-
plegia are not options. Among the various cardiopro-
tective drugs, adenosine has been extensively investi-
gated both in clinical and experimental studies.4,5
Potent cardioprotective effects of adenosine on I-R
injury are derived from reversal of microvascular vaso-
constriction, inhibition of neutrophil functions, reduc-
tion of platelet aggregation, and replenishment of high-
energy stores in endothelial and myocardial cells.5,6
A1-receptor–,7 A2-receptor–,8 and possibly A3-recep-
tor–mediated9 mechanisms are involved in adenosine
cardioprotection.
Accordingly, the present study tested the hypothesis
that the selective delivery of adenosine to a target vessel
with a computer-controlled perfusion delivery pump sys-
tem during simulated off-pump revascularization would
attenuate reperfusion injury, reduce coronary artery
endothelial dysfunction, and salvage myocardium.
Methods
Experimental preparation. All animals received
humane care in compliance with the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council,
and published by the National Academy Press, revised
1996. A total of 18 healthy mongrel dogs were initially
anesthetized with intravenous 2.5% thiopental (20 mg/kg),
followed by an infusion of fentanyl citrate (0.4 µg · kg–1 ·
min–1) and diazepam (0.003 mg · kg–1 · min–1) during the
experiment. Each dog was endotracheally intubated and
mechanically ventilated to maintain PaO2 greater than 100
mm Hg, PaCO2 of 35 to 45 mm Hg, and pH of 7.35 to 7.45.
Metabolic acidemia was corrected with sodium bicarbonate
infusion as needed. Polyethylene catheters were inserted
into the femoral artery bilaterally, with one side being used
for monitoring systemic arterial pressure and microsphere
reference sampling and the contralateral side being used as
an arterial blood source for the coronary arterial perfusion
circuit at the time of reperfusion (Fig 1, A).
The chest was opened by lateral thoracotomy at the fifth
intercostal space, and the pericardium was incised and tented
to cradle the heart. A Millar MPC-500 temperature-compen-
sating solid-state catheter (Millar Instruments, Inc, Houston,
Tex) was placed in the left ventricular cavity through an api-
cal stab wound to measure instantaneous left ventricular pres-
sure. A polyethylene catheter was inserted into the left atrium
for injection of colored microspheres. A proximal portion of
the left anterior descending (LAD) coronary artery was dis-
sected and loosely encircled with a 2-0 silk suture for subse-
quent LAD artery occlusion.
A pair of 5-MHz piezoelectric ultrasonic crystals 2.5 to 3.0
mm in diameter was placed in the subendocardium of the
myocardium perfused by the LAD (ischemic-reperfused seg-
ment) to measure instantaneous segmental dimensions by
means of a sonomicrometer (model 120; Triton Technology,
San Diego, Calif). A model SPC-320 2F solid-state pressure
transducer (Millar Instruments) was inserted into a small
right ventricular branch of the LAD artery distal to the site of
ligation to measure instantaneous LAD intracoronary pres-
sure (Fig 1, A). The position of the transducer catheter did not
interfere with LAD blood flow. The dogs were systemically
heparinized with an initial 300-U/kg dose of heparin sodium
supplemented with 300 U/kg every 90 minutes.
Experimental protocol. The protocol is schematically pre-
sented in Fig 1, B. Hemodynamic and segmental function data
were obtained, and colored microspheres were injected at base-
line. Each dog then received a bolus injection of lidocaine (1.2
mg · kg–1) followed by continuous infusion (0.3 mg · kg–1 ·
min–1), after which the LAD was ligated just distal to the first
diagonal branch for 75 minutes. After LAD ligation, a 2-mm
diameter cannula (DLPlegia Highflow Vessel Cannulae;
Medtronic DLP, Grand Rapids, Mich) was inserted into the
LAD distal to the site of ligation. Ventricular fibrillation, when
encountered, was converted by direct-current countershock of
10 W/s. When more than 4 countershocks were required, ven-
tricular fibrillation was termed intractable, and the experiment
was terminated. At the end of 75 minutes of LAD occlusion, all
data were again collected. The LAD cannula was then attached
to a delivery line from the Myocardial Protection System
(MPS) cardioplegia and perfusion delivery system (Quest
Medical Inc, Allen, Tex), and reperfusion was established by
continuous withdrawal of femoral arterial blood. Mean LAD
pressure was immediately matched to mean systemic arterial
pressure by varying flow rate during the entire reperfusion peri-
od. The dogs were randomly given saline solution vehicle (vehi-
cle group, n = 7) or 10 µmol/L blood adenosine (adenosine
group, n = 7) at a rate of 10 mL/L blood into the LAD during
the first 30 minutes of reperfusion, followed by unmodified
reperfusion for 90 minutes. Adenosine was administered
through side ports situated just proximal to the heart in the per-
fusion line to avoid rapid deamination during transit. After
reperfusion was established with the MPS system, the perfusion
line was used for injection of colored microspheres and with-
drawal of reference samples to determine myocardial blood
flow specifically in the area at risk (AAR). Coronary blood flow
rate was increased to compensate for reference sample with-
drawal from the catheter.
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Data collection and analysis. Hemodynamic data,
including left ventricular, systemic arterial (femoral arteri-
al), and LAD pressures and segmental length data were
acquired during the 10-second period of respiratory apnea.
The data from each channel were digitized and processed by
computer algorithms by means of an interactive video-
graphics program developed in our laboratory (SPEC-
TRUM; Wake Forest University, Winston-Salem, NC), as
described previously.10 Percentage of segmental shortening
was calculated as follows:
100 × (EDL – ESL)/EDL,
where EDL and ESL are end-diastolic length and end-sys-
tolic length, respectively.
Determination of AAR and infarct size. After postexper-
imental excision of the heart, unisperse blue dye was injected
under 100 mm Hg perfusion pressure to stain the normally
perfused region blue and demarcate the AAR. The left ventri-
cle (LV) was cut into 4- to 5-mm thick transverse slices. The
AAR was separated from the nonischemic zone and incubat-
ed for 15 minutes in 1% solution of triphenyltetrazolium
chloride (Sigma Chemical, St Louis, Mo) at 37°C to differ-
entiate the necrotic zone (pale) from the ischemic nonnecrot-
ic zone (red). The AAR was calculated as the sum of the
weights of the nonnecrotic and necrotic tissue within the
AAR divided by the weight of the LV and expressed as a per-
centage (AAR/LV). The infarct size was calculated as the
weight of necrotic tissue divided by the weight of the AAR
(An/AAR) and expressed as a percentage.
Regional myocardial blood flow. Regional myocardial
blood flow (RMBF) with 1 to 2 million 15-µm color-labeled
microspheres (Triton Technology, San Diego, Calif) was cal-
Fig 1. A, Diagram of the surgical preparation and LAD perfusion circuit. After the induction of ischemia, the LAD
was cannulated distal to the occlusive ligature to perfuse the area at risk (hatched area). During the first 30 min-
utes of reperfusion, either adenosine or saline solution was administered by using the computerized additive circuit
through the side ports situated just proximal to the LAD catheter in the perfusion line. B, Experimental protocol.
Time points are indicated for injection of colored microspheres and data collection.
A
B
culated by the reference sampling method, as previously
described.11 Reference samples were withdrawn from the
femoral artery or the perfusion line at a constant rate for 3
minutes. Postexperimental myocardial tissue and reference
blood samples were analyzed with a spectrophotometer
(DU7400; Beckman, Fullerton, Calif). Blood flow was calcu-
lated in the nonischemic epicardium, nonischemic endocardi-
um, AAR epicardium, and the AAR endocardium, respec-
tively, as follows:
RMBF = (CT × FR/CR)/WT,
where CT and CR are the absorbances from dispersed micro-
spheres in the tissue and reference blood samples, respective-
ly; FR is the reference flow rate; and WT is the total weight of
the tissue sample in grams. Results are expressed as milli-
liters per minute per gram of tissue.
Plasma creatine kinase activity. Arterial blood samples
(3 mL) were centrifuged at 2500g and 4°C for 10 minutes.
The plasma was drawn off and analyzed spectrophotomet-
rically for creatine kinase (CK) activity and for protein
concentration (CK-10 kit; Sigma Diagnostics, St Louis,
Mo). Plasma CK activity is expressed as international units
per gram of protein.
Determination of myocardial edema. Postexperimental
transmural myocardial tissue samples were taken from the
nonischemic zone and from the AAR. Each sample was fur-
ther subdivided into subepicardial and subendocardial
regions, blotted of surface moisture, weighed, and desiccated
for 48 hours. The percentage of myocardial water content is
defined as follows:
[(wet weight – dry weight)/wet weight] × 100
Cardiac myeloperoxidase activity. Postexperimental
transmural myocardial tissue samples were taken from the
nonischemic zone and from the nonnecrotic and necrotic
areas of the AAR for spectrophotometric analysis of
myeloperoxidase (MPO) activity as an assessment of neu-
trophil accumulation in myocardium, as described previous-
ly.12 MPO activity is described as the rate of hydrogen per-
oxide degradation–induced color change per minute per 100
mg of tissue and expressed as the change in absorbance units
per minutes per gram of myocardial tissue.
Postexperimental coronary artery endothelial func-
tion. Both the ischemic-reperfused LAD and nonischemic
circumflex coronary arteries (LCx) were carefully dissected
from the heart and cut into rings of approximately 2 mm in
length. The rings were mounted on stainless steel hooks and
placed in organ chambers filled with 37°C Krebs-Henseleit
solution oxygenated with 95% oxygen and 5% carbon diox-
ide, having the following composition: NaCl, 118.1
mmol/L; KCl, 4.7 mmol/L; KH2PO4, 1.2 mmol/L; MgSO4,
1.2 mmol/L; CaCl2 · 2H2O, 2.5 mmol/L; NaHCO3, 25.0
mmol/L; and glucose, 11.1 mmol/L. Changes in isometric
force were measured by isometric force transducers (model
TR001; Radnoti, Monrovia, Calif), as described previous-
ly,10 after 60 minutes of equilibration with 10 µmol/L
indomethacin (INN: indometacin) to prevent vascular
responses to endogenous prostacyclin. The coronary rings
were precontracted with the 10 nmol/L thromboxane A2
mimetic agent U46619 (Upjohn, Kalamazoo, Mich). Once a
stable contraction was observed, cumulative concentration
responses to acetylcholine (Sigma Chemical), a muscarinic
receptor-mediated endothelium-dependent stimulator of
nitric oxide synthase, were obtained. After the rings were
washed with fresh Krebs-Henseleit solution and equilibrat-
ed to baseline, the procedure was repeated for A23187
(Sigma Chemical), a receptor-independent stimulator of
nitric oxide synthase, and for sodium nitroprusside (Sigma
Chemical) to test endothelium-independent vascular smooth
muscle relaxation. Relaxation is expressed as a percentage
of U46619-induced constriction. Drug concentrations are
expressed as the final concentration in the organ chamber.
Statistical analysis. The data were analyzed by 1-way or
2-way analysis of variance for repeated measures to identify
group, time, and group-time interactions. If significant inter-
actions were found, then further pairwise analysis was per-
formed by using post hoc analysis to locate the source of dif-
ferences. Comparisons between the 2 groups in the AAR,
infarct size, MPO activity, myocardial edema, and percentage
of relaxation of coronary rings at each concentration were
analyzed by the nonpaired Student t test. Mean ± SEM values
are reported.
Results
Eighteen animals were initially entered into the
experimental phase of the study. Four were excluded
because of intractable ventricular fibrillation during 75
minutes of LAD occlusion. The remaining dogs were
randomly given saline vehicle (vehicle group, n = 7) or
10 µmol/L blood adenosine (adenosine group, n = 7).
The data from 14 dogs of either sex weighing 22.0 to
31.8 kg (average weight, 27.4 kg) were analyzed and
presented.
Hemodynamic data and segmental function.
Hemodynamic data and segmental shortening during
the course of the experiment are shown in Table I.
There were no significant differences between the 2
groups in any of the hemodynamic variables and seg-
mental shortening in the AAR at baseline. Furthermore,
there were no changes in mean arterial pressure during
the course of the experiment in either group. Note that
delivery of adenosine to the AAR did not produce
hypotension (see R15 in Table I). At ischemia and 15
minutes of reperfusion, left ventricular end-diastolic
pressure increased significantly in the vehicle group
but subsequently returned to the baseline level, and no
significant differences were found between groups.
Ischemia caused paradoxical systolic expansion of the
ischemic segment. During reperfusion, akinesis or
dyskinesis of systolic shortening persisted in both
groups, with no group differences.
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Coronary and myocardial blood flow to the
AAR. LAD blood flow measured by the MPS pump
system during reperfusion is shown in Fig 2.
Reperfusion was achieved by adjusting pump flow to
match LAD pressure to mean arterial pressure. LAD
blood flow was significantly higher in the adenosine
group (146.8 ± 20.7 mL/min) compared with the vehi-
cle group (85.2 ± 5.5 mL/min) at 2 minutes of reper-
fusion. Blood flow remained significantly higher in
the adenosine group during the 30-minute drug deliv-
ery period. After adenosine or saline solution infusion
was discontinued, blood flow promptly decreased in
the adenosine group to levels comparable with those
of the vehicle group (Fig 2). During the remainder of
reperfusion, LAD blood flow remained comparable
between the 2 groups. At the end of 2 hours of reper-
fusion, LAD blood flow averaged 24.0 ± 4.0 mL/min
in the adenosine group and 24.2 ± 5.1 mL/min in the
vehicle group.
RMBF. Results of RMBF in the subepicardial and
subendocardial regions from both ischemic and nonis-
chemic zones measured by colored microspheres are
summarized in Table II. LAD occlusion caused blood
flow in the ischemic subendocardium to decrease sig-
nificantly by 93.4% and 91.6% of baseline in the vehi-
cle and adenosine groups, respectively. This level of
collateral blood flow in the AAR was comparable
between groups. After 15 minutes of reperfusion, there
was a significant reactive hyperemia in the subendo-
cardium in both groups, with that in the adenosine
group being significantly greater than that in the vehi-
cle group. After 120 minutes of reperfusion, blood flow
remained elevated in the AAR subendocardium relative
to baseline values in both groups (38.6% and 162.4%
above baseline in the vehicle and adenosine groups,
respectively), which tended to be greater in the adeno-
sine group. In the AAR subepicardium similar but
moderate changes in regional blood flow were
observed. Blood flow to the nonischemic zone showed
no significant changes in either group during the LAD
occlusion.
AAR and infarct size. The AAR/LV was compara-
ble between groups (Fig 3). The infarct size in the
adenosine group, calculated either as An/LV or
An/AAR (2.6% ± 0.8% and 11.1% ± 3.0%, respective-
ly), was significantly smaller than those values (7.3% ±
1.3% and 28.0% ± 4.0%, respectively) in the vehicle
group (Fig 3).
Plasma CK activity. Plasma CK at baseline was
comparable between the 2 groups (Fig 4, A). After 60
minutes of reperfusion, CK activity was significantly
less in the adenosine group and remained less at the
end of reperfusion compared with that of the vehicle
group (18.4 ± 3.5 vs 8.5 ± 1.2 IU/g protein, respective-
ly). These data are consistent with the significantly
reduced infarct size observed in the adenosine group.
Myocardial edema. After 2 hours of reperfusion, the
myocardium of the vehicle group demonstrated the
greatest myocardial edema in the AAR subendocardi-
um, with tissue water content averaging 85.8% ± 1.2%
(Fig 4, B). In the adenosine group there was a signifi-
cant reduction in myocardial edema in the ischemic
subendocardium (81.9% ± 1.1%) compared with that in
the vehicle group. Myocardial edema in the AAR
subepicardium tended to be lower in the adenosine
group but with no significant difference between the 2
groups. In the normal zone myocardial edema was
comparable between the 2 groups.
Table I. Hemodynamic data and segmental shortening data for the I-R segment
Variable Group Baseline Ischemia R15 R60 R120
HR (beats/min) Vehicle 86.6 ± 11.5 108.7 ± 6.8 111.5 ± 6.6* 110.7 ± 5.8* 126.9 ± 7.7*
Adenosine 69.4 ± 4.5 100.8 ± 8.6* 107.1 ± 7.0* 110.1 ± 11.8* 116.3 ± 8.5*
LVSP (mm Hg) Vehicle 96.0 ± 4.5 84.2 ± 4.4* 83.1 ± 3.7* 81.3 ± 5.3* 85.6 ± 1.8*
Adenosine 88.3 ± 2.0 85.6 ± 5.9 85.1 ± 5.6 86.0 ± 6.3 82.9 ± 5.7
LVEDP (mm Hg) Vehicle 10.4 ± 0.7 14.3 ± 0.9* 13.8 ± 1.2* 12.2 ± 1.1 9.7 ± 0.8
Adenosine 10.3 ± 0.7 14.4 ± 2.1 12.2 ± 1.4 10.7 ± 1.8 8.7 ± 0.9
MAP (mm Hg) Vehicle 77.9 ± 4.1 79.3 ± 7.8 78.6 ± 7.4 74.8 ± 8.7 77.6 ± 4.9
Adenosine 75.8 ± 3.4 78.9 ± 7.6 76.7 ± 7.5 76.9 ± 6.7 72.0 ± 6.6
MLADP (mm Hg) Vehicle 72.9 ± 3.7 18.7 ± 1.9* 72.2 ± 1.2 67.7 ± 4.5 73.5 ± 3.5
Adenosine 68.1 ± 1.6 12.9 ± 1.1* 69.0 ± 5.6 70.4 ± 2.6 67.3 ± 1.2
SS% Vehicle 14.3 ± 2.6 –4.6 ± 1.4* –1.9 ± 2.1* –1.8 ± 1.5* –3.1 ± 1.9*
Adenosine 12.7 ± 1.1 –5.0 ± 0.8* –2.4 ± 1.4* –0.8 ± 2.4* 0.3 ± 2.1*
HR, Heart rate; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; MAP, mean arterial pressure; MLADP, mean LAD pressure;
SS%, percentage of segmental shortening; R15, R60, and R120, 15, 60 and 120 minutes of reperfusion, respectively.
*P < .05 versus baseline.
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Cardiac MPO activity. MPO activity in the nonis-
chemic zone was low and comparable between the 2
groups (Fig 5). In the triphenyltetrazolium chloride–
negative necrotic tissue within the AAR, MPO activity
was 36% less in the adenosine group than in the vehi-
cle group, although there was no statistical difference.
MPO activity in the AAR nonnecrotic tissue was com-
parable between the 2 groups.
Postischemic coronary artery endothelial function.
Vasodilator responses to acetylcholine, A23187, and
sodium nitroprusside in isolated coronary artery rings
taken from the ischemic-reperfused LAD and the nonis-
chemic LCx are summarized in Fig 6. Fig 6, A, shows the
percentage of relaxation with vasodilators in the
ischemic-reperfused LAD rings. The response to acetyl-
choline, an endothelium-dependent and muscarinic
receptor–mediated vasodilator, was significantly greater
in the adenosine group (maximum, 97.9% ± 5.6% relax-
ation with the highest concentration) compared with that
in the vehicle group (maximum, 64.7% ± 6.5%).
Furthermore, endothelium-dependent nonreceptor-medi-
ated vasodilation to A23187 was associated with signifi-
cantly greater relaxation in the adenosine group (maxi-
mum, 84.6% ± 3.5%) than in the vehicle group
Fig 2. Mean LAD coronary artery blood flow (in milliliters
per minute) delivered by the MPS pump system during the
course of reperfusion. R2, R15, R27, R33, R60, and R120, 2,
15, 27, 33, 60, and 120 minutes of reperfusion, respectively;
R30b and R30a, 3 minutes before and after discontinuation of
adenosine or saline solution, respectively. *P < .05 versus the
vehicle group. Veh, Vehicle group; Ado, adenosine group.
Fig 3. Size of the area at risk relative to the left ventricular
mass (AAR/LV) and infarct size as area of necrosis relative to
area at risk (An/AAR). *P < .05 versus the vehicle group. Veh,
Vehicle group; Ado, adenosine group.
Table II. Regional myocardial blood flow for ischemic and nonischemic zone
Ischemic zone Nonischemic zone
Group Epicardium Endocardium Epicardium Endocardium
Baseline Vehicle 0.686 ± 0.073 0.606 ± 0.073 0.609 ± 0.083 0.816 ± 0.106
Adenosine 0.483 ± 0.030 0.368 ± 0.027 0.482 ± 0.068 0.518 ± 0.059
Ischemia Vehicle 0.072 ± 0.035* 0.041 ± 0.014* 0.574 ± 0.063 0.753 ± 0.057
Adenosine 0.065 ± 0.020* 0.029 ± 0.005* 0.523 ± 0.090 0.558 ± 0.069
R15 Vehicle 1.132 ± 0.133* 1.143 ± 0.140* — —
Adenosine 1.429 ± 0.250* 1.550 ± 0.275* — —
R60 Vehicle 0.916 ± 0.090* 0.943 ± 0.107* — —
Adenosine 1.015 ± 0.330 1.164 ± 0.320* — —
R120 Vehicle 0.795 ± 0.108 0.794 ± 0.116 — —
Adenosine 0.856 ± 0.265 0.973 ± 0.255* — —
Values are expressed as milliliters per minute per gram of tissue. Blood flow in the nonischemic zone is absent because of local delivery of microspheres to the area
at risk through the perfusion cannula. R15, R60, and R120, 15, 60, and 120 minutes of reperfusion, respectively.
*P < .05 versus baseline.
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(maximum, 58.7% ± 7.8%). The endothelium-indepen-
dent vasodilator sodium nitroprusside resulted in com-
plete relaxation in both groups, with no significant group
difference. These data indicate that modified reperfusion
with adenosine protects endothelial function from I-R
injury, whereas vascular smooth muscle function remains
intact. Coronary rings taken from nonischemic LCx (Fig
6, B) relaxed comparably by all 3 vasodilators with no
group differences at any concentration.
Discussion
Although beating heart coronary artery bypass graft
operations have recently gained popularity,13,14 the
technique limits the application of cardioprotective
strategies that have been extensively investigated over
the past 20 years (ie, cardioplegia and hypothermia).
During OPCABG, reperfusion after a period of coro-
nary artery occlusion is established without any active
cardioprotection. For the moment, strategies such as
proximal first technique or the use of intraluminal
coronary shunts have been applied to minimizing the
effects of ischemia during elective coronary occlusion,
especially in multivessel OPCABG.15,16 Measures such
as ischemic preconditioning of target vascular beds
have also been advocated, but its effects are not clear,
and clinical efficacy for regional ischemia is not
known.17,18 In this regard the novel PADCAB tech-
nique for off-pump operations allows not only rapid
reperfusion but also the delivery of cardioprotective
agents directly into the ischemic-reperfused target
area.3 The PADCAB technique of coronary perfusion
was originally applied to graft conduits after the com-
pletion of the distal anastomosis. However, with the aid
of an intraluminal device, the target coronary artery can
be perfused directly, thereby avoiding ischemia
induced by vascular snares. This intraluminal perfusion
closely simulates the experimental conditions used in
the present study.
In the present study the myocardium at risk under-
went 75 minutes of ischemia at the time of reperfusion.
This duration of ischemia simulates acute myocardial
infarction rather than routine OPCABG revasculariza-
tion in an elective procedure. However, even during
OPCABG operations, a relatively long ischemic period
may be required, and full perfusion of the target area
may not be achieved until the proximal anastomosis is
completed, thereby involving a longer duration of com-
Fig 4. A, Plasma CK activity during the time course of the
experiment. Base, Baseline; Isch, ischemia; R15, R60, and
R120, 15, 60, and 120 minutes of reperfusion, respectively.
*P < .05 versus the vehicle group. B, Myocardial water con-
tent after desiccation of subendocardial (Endo) and subepi-
cardial (Epi) tissue samples in both area at risk and nonis-
chemic zone at the end of the experiment. *P < .05 versus the
vehicle group. Veh, Vehicle group; Ado, adenosine group.
Fig 5. MPO activity in nonischemic (NI), nonnecrotic (Non-
Nec), and necrotic area at risk of myocardial tissue samples
from each group. Veh, Vehicle group; Ado, adenosine group.
A
B
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promised blood supply. In a patient with a low-grade
stenosis, the ischemia may not extend beyond removal
of the ligature. However, the presence of a severe steno-
sis may impair adequate blood flow until the proximal
anastomosis is completed. Additionally, even the short
ischemic period (usually <15 minutes) necessary for
routine OPCABG may produce subtle injury (metabol-
ic disarrangement or reversible myocardial dysfunc-
tion),19,20 although it may not produce severe injury. In
any event the indications for OPCABG may extend to
patients with acute myocardial infarctions in the future,
for which strategies to attenuate I-R injury will be
important for postoperative cardiac function and
improvement of mortality.
Intracoronary administration of adenosine (10
µmol/L) during the first 30 minutes of reperfusion, as
an additive to the blood perfusing the ischemic myocar-
dial segment, reduced infarct size by 60% of that
observed in the saline vehicle group. This reduction in
infarct size was consistent with previous studies8,21 and
was associated with a significant decrease in plasma
CK activity and myocardial edema. The reduction in
myocardial edema is likely related to preservation of
the microvascular endothelium, consistent with our
Fig 6. Vasodilator response to acetylcholine, A23187, and sodium nitroprusside in ischemic-reperfused LAD (A)
and nonischemic LCx rings (B). *P < .05 versus the vehicle group.Veh, Vehicle group; Ado, Adenosine group.
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data in epicardial vessels. In addition, brief adenosine
treatment significantly attenuated endothelial injury
and tended to reduce the accumulation of neutrophils in
the necrotic AAR. Moreover, the selective intracoro-
nary administration of adenosine did not alter systemic
blood pressure. Hence, transient intracoronary adeno-
sine could be safely delivered to the target vessel
myocardium to attenuate reperfusion injury, although
this reduction of I-R injury was not associated with
recovery of postischemic segmental function at the end
of 2 hours of reperfusion.
Previous studies have demonstrated the potent car-
dioprotective effects of adenosine, including direct
inhibition of neutrophils (superoxide anion generation
and expression of adhesion molecules) and inhibition
of endothelial activation, which attenuated neutrophil-
endothelial interactions.21-23 These effects are largely
mediated by A2a receptor interactions,5,24 although
interaction with the newly identified A3 receptor has
been reported to attenuate neutrophil adherence to
endothelium.9,25 These mechanisms, rather than
increased blood flow, have been suggested to play
major roles in the reduction of infarction after myocar-
dial ischemia and subsequent reperfusion when adeno-
sine was administered at reperfusion.21
The strategy of administering exogenous adenosine
to reduce reperfusion injury has been described
recently,6,21,26,27 and numerous studies have demon-
strated that adenosine can restore various biochemi-
cal alterations with or without functional recov-
ery.5,28,29 Consistent with previous studies in which
adenosine was administered by intracoronary infu-
sion,6,30,31 the present study demonstrated a reduction
of infarct size and preservation of endothelial func-
tion, although postischemic segmental function
showed no recovery, presumably because of our rela-
tively short reperfusion duration. As another possible
reason, it has been demonstrated that neutrophils are
not involved in the pathogenesis of regional contrac-
tile dysfunction,32 although this is still controversial.
Therefore, inhibition of neutrophil actions with
adenosine may not be associated with improvement
of regional segmental function in infarct models.
Considering the short half-life (<15 seconds) of
adenosine in whole blood,33 the most effective
method of adenosine administration is likely to be
selective intracoronary treatment introduced into the
blood just proximal to the coronary catheter.
In the present study 10 µmol/L adenosine was
infused directly into the LAD during the first 30 min-
utes for a total volume of 40 to 60 mL (10-15 mg
adenosine). Although the concentration is fairly low
and the infusion period is short compared with that
found in previous studies,6,30,31 the findings from our
study suggest that our delivery method of adenosine
is effective in salvaging myocardium and attenuating
endothelial injury in the PADCAB setting without
hypotension. The short infusion period is clinically
relevant, especially when PADCAB is used for mul-
tiple grafts, although it is not known whether 30 min-
utes of intracoronary adenosine is optimal. In addi-
tion, the delivery of adenosine can be precisely
controlled by the computerized pump system with an
accuracy of ±1% over a wide range of flow rates.34 In
the present study coronary perfusion pressure was
matched to systemic arterial pressure by varying flow
rate during the entire reperfusion period. It is impor-
tant that coronary pressure is measured directly with
an intraluminal catheter or estimated from trans-
catheter pressure differentials because several previ-
ous studies have demonstrated that there is a safe
limit of pressure for the vulnerable myocardium at
the time of reperfusion, beyond which myocardial
damage (interstitial edema) is observed.35 In this
regard the perfusion pressure used in our study was
comparable with that of passive flow systems,
although the pump flow was not pulsatile.
In summary, the present study determined that intra-
coronary perfusion of at-risk myocardium with adeno-
sine during the first 30 minutes of reperfusion reduced
the extent of myocardial infarction in a simulated PAD-
CAB model. In addition, endothelial function was
highly preserved with adenosine treatment. This novel
reperfusion strategy for OPCABG can be used in cases
requiring single, as well as multiple, grafting and pro-
longed ischemia and for patients with acute evolving
myocardial infarction.
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